Effect of BMP2-Platelet-rich Plasma-Biphasic Calcium Phosphate Scaffold on Accelerated Osteogenesis in Mastoid Obliteration.
The aim of this study was to evaluate the synergistic effect of platelet-rich plasma (PRP) and recombinant human bone morphogenic protein (BMP)-2 on accelerated osteogenesis of hydroxyapatite/β-tricalcium phosphate mixture and biphasic calcium phosphate (BCP) in mastoid obliteration. To the best of our knowledge, there have been no studies reporting the enhancing effects of BCP, combined with BMP2 and PRP, on osteogenesis in mastoid obliteration. Mastoid obliteration was performed in a control group (BCP only, n=7), a group treated with BMP2 and BCP (experimental group I, n=7), and a group treated with BMP2, PRP and BCP (experimental group II, n=7). The animals were administered fluorescent bone labels for a qualitative evaluation of bone formation; oxytetracycline hydrochloride was administered at 2 weeks, calcein at 4 weeks, and alizarin red at 8 weeks. The animals were sacrificed 12 weeks post-surgery and osteogenesis was evaluated by micro-computed tomography, histological investigation, and histomorphometry. Both experimental groups showed accelerated osteogenesis compared to the control group. However, there were no statistically significant differences between experimental groups I and II. From these results, it can be concluded that BMP2 activated BCP for the enhancement of bone regeneration. However, no synergistic effect of BMP2 and PRP on the osteogenesis of BCP was observed.
Department of Otolaryngology, Chonnam National University Medical School, Gwangju, Republic of Korea chulsavio@hanmail.net.
Chul Ho
CH
Jang
Department of Pharmacolocy, Chosun Medical School, Gwangju, Republic of Korea.
Cheol Hee
CH
Choi
Department of Otolaryngology, Chonnam National University Medical School, Gwangju, Republic of Korea.
Yong Beom
YB
Cho
D000818:Animals; D055396:Bone Morphogenetic Protein 2 / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects; D006801:Humans; D006882:Hydroxyapatites / Q000494:pharmacology*; D008416:Mastoid / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000601:surgery; D010012:Osteogenesis / Q000187:drug effects*; D053657:Platelet-Rich Plasma; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000494:pharmacology*; D055114:X-Ray Microtomography
D055396:Bone Morphogenetic Protein 2; D006882:Hydroxyapatites; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C074950:hydroxyapatite-beta tricalcium phosphate; C499469:recombinant human bone morphogenetic protein-2
Biphasic calcium phosphate; bone morphogenic protein-2; platelet-rich plasma